Business & Regulation

Recently, Tim Mackey and colleagues examined the extent to which counterfeit drugs had penetrated global legitimate supply chains.

The EMA fights to reinstate its former executive director – and the FDA’s new leader is still unconfirmed

Expedited regulatory approvals bring medicines to market faster – but are they the right drugs?

Mislabeled, substandard or falsified medicines are the perfect opportunity for criminals looking for low risks and high rewards.

Is it time to update your resume and fine-tune your interview skills?

Sitting Down With... David Baltimore, Nobel Laureate, President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology, USA.

Learning when to abandon an R&D project can open the door to potential future gains.

CPhI Worldwide 2015 in Madrid is just around the corner. Are you ready for showtime?

Drug companies claim that off-label drug promotion is protected by freedom of speech.

Dissecting a ligand into smaller fragments can provide a strategy for analyzing the role of key functional groups in a protein-ligand interaction.